Sunshine Biopharma
SBFM
6 hedge funds and large institutions have $800K invested in Sunshine Biopharma in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, reducing their positions, and 4 closing their positions.
4.44% less ownership
Funds ownership: 8.9% → 4.46% (-4.4%)
14% less funds holding
Funds holding: 7 → 6 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
77% less capital invested
Capital invested by funds: $3.55M → $800K (-$2.75M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$1.37M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$97.7K |
| 3 |
DWM
Dakota Wealth Management
Palm Beach Gardens,
Florida
|
+$48.8K |
| 4 |
VF
Virtu Financial
New York
|
+$48.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.56M |
| 2 |
EAM
Empery Asset Management
New York
|
-$1.1M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$720K |
| 4 |
Jane Street
New York
|
-$31K |
SBFM Hedge Fund Activity: Q2 2022 in Review
6 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Sunshine Biopharma (SBFM) for Q2 2022, worth a combined $800K — down 77% from $3.55M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SBFM and 3 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $1.37M. The largest seller was Armistice Capital, exiting entirely with an estimated $1.56M sold.
- 6 institutional investors held Sunshine Biopharma (SBFM) as of Q2 2022, down from 7 in Q1 2022.
- Funds reported $800K of Sunshine Biopharma stock for Q2 2022, down 77% quarter-over-quarter.
- 3 funds opened new Sunshine Biopharma positions in Q2 2022 and 4 closed out, a net change of -1 holder.
- The largest Sunshine Biopharma buyer in Q2 2022 was Bridgeway Capital Management, an estimated $1.37M added.
- The largest Sunshine Biopharma seller in Q2 2022 was Armistice Capital, an estimated $1.56M sold.
Based on aggregated 13F filings for Q2 2022.